Literature DB >> 16246083

Azole susceptibility and resistance in Candida dubliniensis.

E Pinjon1, G P Moran, D C Coleman, D J Sullivan.   

Abstract

Candida dubliniensis is a recently described species of pathogenic yeast that shares many phenotypic features with Candida albicans. It is primarily associated with oral colonization and infection in HIV-infected individuals. Isolates of C. dubliniensis are generally susceptible to commonly used azole antifungal agents; however, resistance has been observed in clinical isolates and can be induced by in vitro exposure. Molecular mechanisms of azole resistance in C. dubliniensis include increased drug efflux, modifications of the target enzyme and alterations in the ergosterol biosynthetic pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246083     DOI: 10.1042/BST20051210

Source DB:  PubMed          Journal:  Biochem Soc Trans        ISSN: 0300-5127            Impact factor:   5.407


  10 in total

1.  Do hospital microbiology laboratories still need to distinguish Candida albicans from Candida dubliniensis?

Authors:  Shawn R Lockhart
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

2.  Comparative transcript profiling of Candida albicans and Candida dubliniensis identifies SFL2, a C. albicans gene required for virulence in a reconstituted epithelial infection model.

Authors:  Martin J Spiering; Gary P Moran; Murielle Chauvel; Donna M Maccallum; Judy Higgins; Karsten Hokamp; Tim Yeomans; Christophe d'Enfert; David C Coleman; Derek J Sullivan
Journal:  Eukaryot Cell       Date:  2009-12-18

3.  Longitudinal genotyping of Candida dubliniensis isolates reveals strain maintenance, microevolution, and the emergence of itraconazole resistance.

Authors:  M Fleischhacker; J Pasligh; G Moran; M Ruhnke
Journal:  J Clin Microbiol       Date:  2010-03-03       Impact factor: 5.948

4.  An MDR1 promoter allele with higher promoter activity is common in clinically isolated strains of Candida albicans.

Authors:  Igor Bruzual; Carol A Kumamoto
Journal:  Mol Genet Genomics       Date:  2011-10-05       Impact factor: 3.291

5.  Paradoxical growth of Candida dubliniensis does not preclude in vivo response to echinocandin therapy.

Authors:  Marçal Mariné; F Javier Pastor; Ismail H Sahand; José Pontón; Guillermo Quindós; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2009-09-28       Impact factor: 5.191

6.  Candida dubliniensis encrustation of an obstructing upper renal tract calculus.

Authors:  Dermot O'Kane; Anthony Kiosoglous; Kay Jones
Journal:  BMJ Case Rep       Date:  2013-08-23

7.  Identification of Candida albicans by using different culture medias and its association in potentially malignant and malignant lesions.

Authors:  Sonal Saigal; Ankur Bhargava; S K Mehra; Falguni Dakwala
Journal:  Contemp Clin Dent       Date:  2011-07

Review 8.  Uncommon opportunistic fungal infections of oral cavity: A review.

Authors:  Ag Deepa; Bindu J Nair; Tt Sivakumar; Anna P Joseph
Journal:  J Oral Maxillofac Pathol       Date:  2014-05

Review 9.  Candidiasis and Mechanisms of Antifungal Resistance.

Authors:  Somanon Bhattacharya; Sutthichai Sae-Tia; Bettina C Fries
Journal:  Antibiotics (Basel)       Date:  2020-06-09

10.  Performance comparison of phenotypic and molecular methods for detection and differentiation of Candida albicans and Candida dubliniensis.

Authors:  Suhail Ahmad; Ziauddin Khan; Mohammad Asadzadeh; Ajmal Theyyathel; Rachel Chandy
Journal:  BMC Infect Dis       Date:  2012-09-25       Impact factor: 3.090

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.